Xiamen Amoytop Biotech Valuation
Is 688278 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Por debajo del valor justo
Muy por debajo del valor justo
Price-To-Earnings vs. similares
Price-To-Earnings vs. Industria
PM vs. Ratio Justo
Pronóstico de los analistas
Share Price vs Fair Value
What is the Fair Price of 688278 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Por debajo del valor justo: 688278 (CN¥59.32) cotiza por encima de nuestra estimación de valor razonable (CN¥52.89)
Muy por debajo del valor justo: 688278 cotiza por encima de nuestra estimación del valor razonable.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 688278?
Other financial metrics that can be useful for relative valuation.
| What is 688278's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | CN¥26.52b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 12.3x |
| Enterprise Value/EBITDA | 36.3x |
| PEG Ratio | 1.8x |
Price to Earnings Ratio vs Peers
How does 688278's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 52.2x | ||
688363 Bloomage BioTechnology | 45.5x | 39.1% | CN¥26.7b |
000403 Pacific Shuanglin Bio-pharmacy | 36.9x | 19.3% | CN¥20.8b |
300142 Walvax Biotechnology | 58.6x | 33.8% | CN¥24.6b |
300601 Shenzhen Kangtai Biological Products | 67.9x | 47.1% | CN¥24.5b |
688278 Xiamen Amoytop Biotech | 47.8x | 26.9% | CN¥26.5b |
Price-To-Earnings vs. similares: 688278 es un buen valor basado en su Ratio Price-To-Earnings (45.5x) comparado con la media de sus homólogos (45.8x).
Price to Earnings Ratio vs Industry
How does 688278's PE Ratio compare vs other companies in the CN Biotechs Industry?
Price-To-Earnings vs. Industria: 688278 es caro en función de su Ratio Price-To-Earnings (53x) en comparación con la media del sector CN Biotechs (33.4x).
Price to Earnings Ratio vs Fair Ratio
What is 688278's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 47.8x |
| Fair PE Ratio | 31.6x |
PM vs. Ratio Justo: 688278 es caro en función de su Ratio Price-To-Earnings (47.9x) comparado con el Ratio Price-To-Earnings estimado (38.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Pronóstico de los analistas: Datos insuficientes para mostrar el pronóstico de precios.